Immunotherapy in Melanoma: Highlights for the General Practitioner

Area of Science:

• Oncology
• Immunology

Background:

• Melanoma is an aggressive skin cancer; surgery is standard for localized disease.
• Relapse risk persists post-surgery, especially for advanced or node-positive melanomas.
• Immune checkpoint inhibitors (ICIs) show promise in improving survival post-surgery.

Purpose of the Study:

• To review the efficacy of current immunotherapies for melanoma.
• To discuss novel immunotherapeutic strategies and combinations.
• To emphasize the importance of multidisciplinary teams in treatment decisions.

Main Methods:

• Review of clinical trial data on ICIs in melanoma.
• Analysis of outcomes for stage-II, III, and metastatic melanoma.
• Discussion of emerging immunotherapeutic approaches.

Main Results:

• Adjuvant immunotherapy with ICIs improves relapse-free and distant metastasis-free survival in stage-III and high-risk stage-II melanoma.
• Combination immunotherapy (anti-PD-1 + anti-CTLA-4) offers long-term survival for over 50% of patients with unresectable or metastatic melanoma.
• Novel therapies like anti-LAG-3, adoptive cell therapy, and vaccines are under investigation.

Conclusions:

• Immunotherapy has significantly advanced melanoma treatment, particularly after surgery.
• Ongoing research focuses on overcoming resistance and improving survival through novel combinations.
• Personalized treatment strategies require multidisciplinary team input.